Amyotrophic Lateral Sclerosis (ALS) remains one of the most difficult neurodegenerative diseases in modern medicine. Despite major advances in molecular biology, genomics, biomarker science, and regenerative medicine, patients still face a largely fatal prognosis and very limited therapeutic options.

The regulatory evaluation of emerging ALS therapies has exposed deeper tensions inside the modern FDA. Existing approval structures were largely designed around traditional pharmaceuticals, large populations, and relatively uniform disease models. ALS is none of those things. The disease progresses unevenly, patient populations are small, and therapeutic effects may emerge differently across stages of illness.

Over the past decade, the FDA has publicly embraced accelerated approval pathways, adaptive trial design, patient-focused drug development, and biomarker-driven regulation. Yet these principles have not always been applied consistently in practice.

This paper argues that ALS has become an important stress test for whether American regulatory institutions can adapt to twenty-first century biomedical science. The discussion extends beyond any single therapy or sponsor. It touches broader questions involving administrative consistency, evidentiary flexibility, patient autonomy, and the future competitiveness of the American biotechnology sector.

Using ALS therapeutics and regenerative medicine as case studies, this article examines evolving FDA policy regarding accelerated approval, Bayesian statistical methodologies, biomarker qualification, Special Protocol Assessments, and regenerative medicine oversight. It also considers the ethical consequences of regulatory delay in terminal disease.

The larger issue is no longer whether regulatory modernization is necessary. That debate has largely been settled. The issue now is whether review culture and operational decision-making will evolve quickly enough to keep pace with scientific reality.

ALS has long been viewed as one of the most unforgiving areas in drug development. More than a century after Jean-Martin Charcot first characterized the disease, patients diagnosed with ALS still face rapid neurological decline and overwhelmingly fatal outcomes. Roughly 30,000 Americans currently live with ALS, and military veterans continue to experience elevated incidence rates.

The scientific challenges are substantial. ALS progresses unpredictably. Patients decline at different rates. Multiple pathological pathways appear to be involved simultaneously. Conventional clinical trial models often struggle to detect meaningful therapeutic effects inside small and biologically heterogeneous populations.¹

At the same time, the scientific landscape has changed dramatically. Biomarker science, genomic analysis, antisense technologies, autologous stem cell approaches, and precision medicine strategies have all advanced rapidly over the past decade. Regulatory culture has moved more slowly.

As Pitts has argued elsewhere, “product failure is not process failure.”² A disappointing study outcome does not invalidate the broader regulatory mechanisms designed to encourage innovation in fatal disease. That distinction matters. Rare disease regulation increasingly requires evaluating incomplete but clinically meaningful evidence under conditions of unavoidable uncertainty.³ ALS now sits near the center of that debate.⁴

The controversy surrounding therapies such as NurOwn is therefore not simply about one company or one product. It reflects a larger institutional question: can the FDA apply modern scientific tools consistently when therapies fall outside conventional pharmaceutical models?

Other countries are already answering that question more aggressively. Japan has implemented conditional approval structures for regenerative medicine products. China continues investing heavily in cell therapy infrastructure and expedited translational pathways. South Korea and Singapore have adopted similarly adaptive frameworks.

While the FDA debate’s evidentiary philosophy, competitors are building industries.

Over the past twenty years, Congress and the FDA have created multiple mechanisms intended to accelerate therapeutic development in areas of serious unmet medical need. These include Accelerated Approval, Fast Track designation, Breakthrough Therapy designation, RMAT designation, and expanded use of surrogate biomarkers.⁵

The Agency has also endorsed patient-focused drug development initiatives, adaptive trial methodologies, Bayesian statistics, and real-world evidence integration.^6,7 On paper, the modernization agenda is clear. In practice, implementation has often been uneven. The review process surrounding regenerative medicine products continues to reveal a persistent institutional conservatism, particularly toward autologous cellular therapies. Unlike traditional small molecules, autologous therapies involve individualized manufacturing, biological variability, and mechanisms that may not generate clean binary clinical signals.

That complexity does not automatically imply scientific weakness. It may simply reflect the biological realities of advanced therapies. Traditional frequentist statistical models were designed for more uniform disease states and more standardized interventions. ALS rarely behaves that way. Yet review structures inside parts of the Agency still appear calibrated toward conventional paradigms.

Guidance documents change quickly. Reviewer instincts often do not. In fatal diseases with small patient populations, uncertainty is inevitable. The more difficult question is how much uncertainty regulators are willing to tolerate when patients have little time left and few meaningful alternatives. For ALS patients, delay is not abstract. Disease progression continues while evidentiary debates unfold.

The implications of these debates extend well beyond ALS. Regenerative medicine—including cell therapies, gene editing technologies, engineered biologics, and individualized therapeutics—is rapidly becoming one of the most strategically important sectors in biomedical science. These technologies are expected to reshape treatment approaches across neurodegenerative disease, oncology, autoimmune disorders, cardiovascular disease, and rare genetic conditions.

Historically, the United States dominated biomedical innovation through a combination of academic excellence, venture investment, entrepreneurial culture, and regulatory credibility. Alas, that leadership is no longer guaranteed.

Japan’s regenerative medicine framework permits conditional patient access while confirmatory evidence continues to develop. China has aggressively expanded translational infrastructure and hospital-based treatment pathways. Other countries increasingly view regulatory agility as an economic strategy as much as a public health policy. Regulatory predictability now influences where companies build manufacturing facilities, deploy clinical programs, and raise capital.

If advanced therapies encounter prolonged uncertainty or inconsistent evidentiary expectations in the United States, investment will migrate elsewhere. Some of that movement has already begun. This is not simply a scientific issue, it’s also industrial policy.

Recent proposals suggesting that Institutional Review Boards should evaluate the financial stability of biotechnology sponsors before allowing clinical trials misunderstand how modern biotechnology functions.

Most early-stage biotechnology companies operate through milestone-based financing structures. Capital is raised incrementally as scientific and regulatory progress occurs. That is not dysfunction. It is the standard architecture of biotech innovation.

Many transformative rare disease programs originate from small companies operating with limited capital and significant scientific risk. Requiring fully secured long-term financing before trial initiation would eliminate many of the most innovative therapeutic efforts before they begin. The practical result would favor only the largest pharmaceutical companies and the safest incremental programs.

Ethical oversight should focus on scientific validity, operational competence, patient safety, and informed consent. Financial uncertainty and ethical misconduct are not the same thing. Biotechnology innovation is inherently volatile. Attempts to regulate volatility out of the system may also regulate innovation out of the system.⁸

The FDA’s decision to grant a Special Protocol Assessment (SPA) for the NurOwn Phase 3b study represented a significant regulatory milestone. An SPA is not symbolic. It is the product of extensive negotiation between sponsor and Agency regarding trial design, endpoints, statistical methodology, and the adequacy of the overall framework to answer the relevant clinical questions. In practical terms, an SPA functions as a scientific contract.

By granting the SPA, the FDA formally acknowledged that the proposed study design constituted a legitimate and scientifically appropriate pathway for evaluation. That matters because later criticisms attacking the scientific legitimacy of the program inevitably raise questions about consistency inside the Agency itself.

The NurOwn SPA also carried historical significance as the first SPA granted by the FDA for an ALS program. That decision reflected recognition inside the Agency that conventional trial structures may not fully capture therapeutic signals in rapidly progressive neurodegenerative disease.

Rare disease development depends heavily on predictability. Investors, researchers, clinicians, and patients all make long-term decisions based partly on how they believe the FDA will interpret evidence. If formal Agency agreements can later become fragmented across divisions or reinterpreted unpredictably, confidence deteriorates.

Process matters. The FDA does not need to guarantee approval outcomes. But stakeholders must be able to trust that formally negotiated scientific standards will be applied consistently and transparently.

ALS exposes one of the central methodological tensions in modern drug development. Traditional randomized controlled trial models were designed around relatively homogeneous populations and comparatively straightforward therapeutic mechanisms. ALS is neither homogeneous nor straightforward. Disease progression varies dramatically between patients. Genetic drivers differ. Biomarker profiles evolve over time. Therapeutic responsiveness may depend heavily on disease stage and timing of intervention. Subgroup analyses therefore become especially important.

Historically, regulators have viewed subgroup findings cautiously, particularly when concerns exist regarding post hoc interpretation. That caution is understandable. But excessive skepticism can itself become a form of rigidity. When prespecified subgroups demonstrate statistically significant effects in biologically plausible populations, those signals deserve serious consideration rather than automatic dismissal.

Modern statistical science increasingly supports more adaptive approaches capable of integrating multiple streams of evidence. Bayesian methodologies, longitudinal biomarker analysis, external controls, and real-world evidence all offer tools better suited to complex diseases.^6,7

The FDA has already begun moving in this direction. Bayesian reasoning is especially relevant in ALS because it allows regulators to synthesize heterogeneous clinical signals into a coherent evidentiary picture. Rather than treating each dataset as isolated, Bayesian models permit earlier evidence to inform interpretation of later findings.

In the context of NurOwn, long-term survival observations and functional outcomes emerging from the Expanded Access Program may reasonably function as informative priors supporting interpretation of Phase 3 subgroup signals. That is not a lowering of standards. It is an acknowledgment that evidence generation in neurodegenerative disease is iterative, cumulative, and biologically complex.

The FDA’s approval of Qalsody (tofersen) for SOD1-associated ALS marked an important moment in the evolution of ALS regulation.⁹ The Agency granted Accelerated Approval largely on the basis of reductions in neurofilament light chain (NfL), a biomarker associated with neurodegeneration. The pivotal trial itself did not demonstrate definitive clinical benefit on its primary endpoint at the time of approval.

The FDA nevertheless concluded that the biomarker evidence was reasonably likely to predict clinical benefit and that was a consequential action.

Accelerated Approval has never required absolute certainty. It requires a reasonable evidentiary basis under conditions of serious unmet medical need. Recent ALS regulatory developments suggest that the FDA is gradually adopting a more biomarker-centered evidentiary model. Decisions involving Qalsody, together with evolving Agency engagement with programs such as Clene’s CNM-Au8, indicate movement toward a regulatory framework grounded increasingly in biomarker inference, longitudinal disease trajectories, and integrated evidence synthesis.

Once the Agency establishes an acceptable evidentiary framework for one sponsor, principles of administrative consistency require that comparable standards apply to similarly situated programs demonstrating analogous biological or clinical signals. Regulatory flexibility cannot become an ad hoc exercise available only to selected technologies or companies.

Public trust depends heavily on consistency. If one ALS therapy can receive biomarker-driven flexibility under accelerated approval principles, regulators must explain clearly why another program operating under similar evidentiary logic should be treated differently.

The 2023 Peripheral and Central Nervous System Drugs Advisory Committee discussions surrounding ALS therapies demonstrated how differently statisticians, clinicians, reviewers, and patients can interpret the same data.

The disagreement extended beyond endpoint performance. It involved subgroup interpretation, biomarker significance, acceptable uncertainty thresholds, and the role of patient urgency in regulatory decision-making.

The structure of the process itself also became controversial. Several participants argued that the unusually large advisory committee format, compressed discussion periods, and extensive generalized presentations limited meaningful scientific exchange regarding the underlying data. At points during the meeting, sponsor representatives and invited experts had little time to respond to statistical criticisms that shaped much of the broader discussion. Those concerns should not be dismissed as procedural footnotes.

In diseases like ALS, where evidentiary interpretation is inherently difficult, trust in the fairness of the process becomes critically important. Patients and clinicians must believe that competing interpretations are being heard fully and evaluated openly. Scientific legitimacy depends partly on scientific process.

Congress passed the ACT for ALS legislation because lawmakers recognized that traditional drug development structures were poorly suited for rapidly progressive neurodegenerative disease.¹⁰

The legislation encouraged greater collaboration between FDA and NIH, expanded support for innovative trial design, promoted biomarker development, strengthened expanded access pathways, and emphasized the importance of faster therapeutic evaluation.

The FDA later released a Rare Neurodegenerative Diseases Action Plan highlighting adaptive trial methodologies, biomarker qualification, public-private collaboration, real-world evidence integration, and expanded patient access mechanisms.^11,12,13 The policy direction is now unmistakable, and the larger challenge is implementation.

One of the most important institutional issues facing the FDA today is the gap between leadership-level modernization policy and reviewer-level practice. Congress, senior Agency leadership, and multiple guidance documents now openly support adaptive statistical methodologies, biomarker-driven inference, and patient-centered evidentiary flexibility in ALS.

Yet operational culture inside review divisions can remain considerably more cautious. Older evidentiary instincts developed around conventional pharmaceutical models do not disappear overnight. Large homogeneous populations, clean endpoint separation, and highly standardized interventions remain the implicit baseline in many review settings. ALS rarely conforms to those assumptions.

Fully operationalizing the ACT for ALS mandate therefore requires more than new guidance documents. It requires cultural adaptation inside the Agency itself. Reviewer training matters. Leadership signaling matters. Institutional incentives matter, otherwise modernization risks remaining largely rhetorical.

The ethical dimensions of ALS regulation cannot be separated from the reality of the disease itself. Traditional regulatory models often treat time as neutral—as though waiting simply improves decision quality. In ALS, time is a clinical variable. Patients who deteriorate during prolonged review cycles may never live long enough to benefit from eventual approvals.

That reality does not eliminate the need for scientific rigor, but it does change the ethical calculus.

In criminal law, societies have long accepted that convicting an innocent person may represent a greater injustice than allowing a guilty person to go free. A similar asymmetry exists in terminal disease regulation.

The greater ethical danger may not be approving a therapy that later proves only modestly effective. The greater danger may be rejecting a therapy that could meaningfully preserve life or function because statistical certainty remained incomplete. False negatives carry moral consequences. For ALS patients, regulatory inaction is not neutral. Delayed access can become irreversible clinical harm.

Patients facing terminal illness frequently express willingness to tolerate uncertainty in exchange for potential benefit. Truly patient-centered regulation requires incorporating that risk tolerance into evidentiary decision-making rather than treating it as a symbolic consideration.

The FDA remains the world’s most influential drug regulatory agency. Its decisions shape investment flows, development strategies, scientific priorities, and international regulatory norms and that influence ultimately depends on trust.

Regenerative medicine will continue challenging conventional review structures. Artificial intelligence-assisted diagnostics, individualized cellular therapies, genomic editing technologies, and adaptive precision medicine approaches will generate increasingly complex data environments.

The FDA does not need to abandon rigor to meet those challenges, but the Agency will need review systems capable of evaluating therapies that do not behave like traditional pharmaceuticals.

Modernization is not deregulation.¹⁴ It is the development of smarter evidentiary tools capable of integrating biomarker science, adaptive trial design, conditional evidence generation, patient-centered outcomes, and real-world clinical data into coherent regulatory decisions. A system unable to adapt to scientific complexity risks undermining both public health and American biomedical leadership.

The tensions surrounding ALS therapeutics are not unprecedented. Over the past decade, the FDA has repeatedly confronted difficult questions involving surrogate biomarkers, accelerated approval, small patient populations, and severe unmet medical need. The approval of Sarepta’s Exondys 51 for Duchenne muscular dystrophy remains one of the clearest examples. In 2016, the FDA granted accelerated approval largely based on dystrophin production despite substantial internal disagreement regarding the adequacy of the evidence.¹⁵

The Aduhelm controversy generated similar institutional conflict. Critics questioned the strength of the clinical data and the reliance on amyloid reduction as a surrogate marker. Supporters argued that Alzheimer’s disease demanded greater regulatory flexibility in the face of catastrophic unmet need.¹⁶ Other precedents point in a different direction.

Luxturna and Zolgensma demonstrated how adaptive regulatory approaches could accelerate access to transformative therapies in rare genetic disease.^17,18 CAR-T therapies forced the FDA to build review systems capable of evaluating highly individualized manufacturing models and unprecedented logistical complexity.¹⁹ Each case required the Agency to stretch beyond traditional pharmaceutical assumptions. ALS now occupies a similar position.

The larger challenge facing modern regulators is how to evaluate therapies characterized by biological complexity, evolving biomarkers, heterogeneous progression patterns, and urgent patient need without sacrificing scientific credibility. That tension is unlikely to disappear. If anything, it will become more common. Regulatory flexibility that exists only on paper is, for a terminal patient, the same as no flexibility at all.

The debate surrounding ALS therapeutics reflects a larger turning point in biomedical regulation. Regenerative medicine, biomarker-driven approvals, adaptive statistical methodologies, and individualized therapeutics are no longer speculative concepts. They are becoming central features of modern medicine.

The FDA has already acknowledged much of this transformation through Accelerated Approval, RMAT designation, the ACT for ALS initiative, and expanded support for innovative trial methodologies.

The remaining challenge is consistency.

ALS patients have shown extraordinary courage in the face of relentless disease progression. Researchers and developers continue pursuing therapies despite enormous scientific and financial uncertainty.

Future policy decisions will determine whether American regulatory institutions can evaluate these therapies using standards aligned with contemporary biomedical science rather than frameworks inherited largely from another era. The future of rare disease innovation may very well depend on the answer.

1.

van Eijk RPA, Nikolakopoulos S, Roes KCB, Middelkoop BM, Ferguson TA, Shaw PJ, Leigh PN, Al-Chalabi A, Eijkemans MJC, van den Berg LH. Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials. J Neurol Neurosurg Psychiatry. 2019 Dec;90(12):1331-1337. doi: 10.1136/jnnp-2019-320998. Epub 2019 Jul 10. PMID: 31292200; PMCID: PMC6902062.

2.

Pitts PJ. Product Failure Is Not Process Failure. RealClearHealth. 2024.

3.

Pitts PJ. Regulatory Flexibility Can Accelerate Rare Disease Drug Development. BioSpace. 2024.

4.

Pitts PJ. ALS, accelerated approval, and the future of FDA modernization. Biocentury. 2025.

5.

U.S. Food and Drug Administration. Guidance for Industry: Expedited Programs for Serious Conditions—Drugs and Biologics. Silver Spring, MD: FDA; 2014.

6.

Berry DA. Bayesian clinical trials. Nat Rev Drug Discov. 2006;5(1):27–36.

7.

Eichler HG, Pignatti F, Schwarzer-Daum B, et al. Randomized controlled trials versus real world evidence: neither magic nor myth. Clin Pharmacol Ther. 2021;109(5):1212–1218.

8.

Hwang TJ, Carpenter D, Lauffenburger JC, Wang B, Franklin JM, Kesselheim AS. Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Intern Med. 2016;176(12):1826–1833.

9.

U.S. Food and Drug Administration. FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene. FDA News Release. Apr. 25, 2023.

10.

U.S. Congress. Accelerating Access to Critical Therapies for ALS Act (ACT for ALS). Public Law 117-79; 2021.

11.

U.S. Food and Drug Administration. Rare Neurodegenerative Diseases Including Amyotrophic Lateral Sclerosis (ALS): Action Plan. Silver Spring, MD: FDA; 2024.

12.

Cudkowicz ME, van den Berg LH, Shefner JM, et al. Diroximel fumarate as a platform for adaptive and biomarker-driven ALS clinical development. Muscle Nerve. 2023;67(2):123–131.

13.

Jarow JP, Lemery S, Bugin K, Khozin S, Moscicki R. Overview of FDA’s expanded access program for investigational drugs. Ther Innov Regul Sci. 2017;51(2):177–179.

14.

1. Kesselheim AS, Avorn J. New “21st Century Cures” legislation: speed and ease vs science. JAMA. 2017;317(6):581–582.

15.

U.S. Food and Drug Administration. FDA grants accelerated approval to eteplirsen for Duchenne muscular dystrophy. 2016.

16.

Dunn B, Stein P, Temple R, et al. An appropriate use of accelerated approval—Aducanumab for Alzheimer’s disease. N Engl J Med. 2021;385(9):856–857.

17.

Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophy. Lancet. 2017;390(10097):849–860.

18.

Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713–1722.

19.

Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–448.